

Special Issue

Bacterial and Viral Immunity and Vaccination

Message from the Guest Editor

Bacterial and viral infectious diseases pose an ongoing threat to human health, with significant impacts on the public health sector and economic development of affected populations. Compared to other global regions, low- and middle-income countries (LMIC), including those within Sub-Saharan Africa, generally bear a larger burden of these infectious (and often preventable) diseases. It is important that control of and vaccination against infectious diseases within this region continues. This Special Issue aims to present research articles related to the immunology of bacterial and viral pathogens, vaccine immunogenicity, efficacy and effectiveness and factors influencing vaccine performance. Contributions relating to studies or vaccine trials performed in LMIC are also welcome. We are also research (or review) articles that discuss: (i) laboratory-based immunology and/or vaccine studies (ii) on bacterial and/or viral pathogens (iii) using qualitative and/or quantitative approaches in (iv) either pediatric and/or adult populations from different global regions, including LMIC.

Guest Editor

Dr. Martin R. Goodier

MRC Unit The Gambia, London School of Hygiene and Tropical Medicine, London, UK

Deadline for manuscript submissions

closed (31 August 2024)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/159636

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X), founded in 2013, now has a firm history of publishing peer-reviewed, state-of-the-art research papers on vaccines and vaccination in the broadest sense. Areas covered include, but are not limited to, novel and emerging vaccine technologies, building on in-depth knowledge of what constitutes a protective immune response. These can be new vaccines for old diseases, or old vaccines for new diseases. Vaccines against cancer and autoimmune diseases explicitly are also within the scope of the journal. Because public opinion and even government policies towards vaccines and vaccination have changed, vaccine policy and public health issues are major concerns. Climate change will also have an impact on the spread of infectious diseases, and thus also on vaccine and vaccination policies worldwide.

Editor-in-Chief

Prof. Dr. Ger Rijkers

Department of Health, Cognition and Behavior, University College
Roosevelt, 4331 CB Middelburg, The Netherlands

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.1 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).